Manchester Dialysis Center is a medicare approved dialysis facility center in Manchester, Connecticut and it has 31 dialysis stations. It is located in Hartford county at 319 Main Street, Manchester, CT, 06040. You can reach out to the office of Manchester Dialysis Center at (860) 432-9499. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. Manchester Dialysis Center has the following ownership type - Non-Profit. It was first certified by medicare in September, 2009. The medicare id for this facility is 072538 and it accepts patients under medicare ESRD program.
| Name | Manchester Dialysis Center |
|---|---|
| Location | 319 Main Street, Manchester, Connecticut |
| No. of Dialysis Stations | 31 |
| Medicare ID | 072538 |
| Managed By | Dialysis Clinic, Inc. |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 319 Main Street, Manchester, Connecticut, 06040 | |
| (860) 432-9499 | |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
| NPI Number | 1982832317 |
| Doing Business As | Dialysis Clinic Inc. |
| Address | 319 Main St Manchester, Connecticut, 06040 |
| Phone Number | (860) 678-1459 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 50 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 70 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 613 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
| Adult patients getting regular peritoneal dialysis at the center | 15 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 120 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 88 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Manchester Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 83 |
| Hypercalcemia patient months | 776 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 89 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 22 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 54 |
| Patient months included in arterial venous fistula and catheter summaries | 471 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 63 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 3 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 62 |
| Hospitalization Rate in facility | 148 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 266.1 |
| Hospitalization Rate: Lower Confidence Limit | 85 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Manchester Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 38.3 |
| Readmission Rate: Lower Confidence Limit | 16.9 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Manchester Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.1 (As Expected) |
| SIR: Upper Confidence Limit | 2.66 |
| SIR: Lower Confidence Limit | .35 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Manchester Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 52 |
| Transfusion Rate in facility | 17.1 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 65.2 |
| Transfusion Rate: Lower Confidence Limit | 5.3 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Manchester Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 329 |
| Mortality Rate in facility | 14.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 20 |
| Mortality Rate: Lower Confidence Limit | 10.9 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago
Manchester Dialysis Center Location: 319 Main Street, Manchester, Connecticut, 06040 Phone: (860) 432-9499 |
News Archive
Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.
CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.
Derma Sciences, Inc., a specialty medical device and pharmaceutical company focused on advanced wound care, today announced that it has signed an exclusive distribution agreement with Medline Industries for sales of one of its key products – BIOGUARD™ Barrier Dressing – into the acute care market. Medline is the 2nd leading provider of traditional wound care products into Acute Care facilities, with over 800 sales representatives. Sales will begin this month.
Researchers from the Indiana University Center for Aging Research and the Regenstrief Institute have performed the first study conducted in the United States under real-world conditions comparing patient adherence and tolerability to a class of drugs known as cholinesterase inhibitors.
KaVo Kerr Group, a global portfolio of leading dental brands, plans to present 35+ new products at the 36th International Dental Show (IDS) in Cologne. KaVo Kerr Group delivers products and solutions to 99% of dental practices worldwide, making IDS — the world's leading trade fair for the dental industry — the ideal stage to share the latest KaVo Kerr Group has to offer.
› Verified 3 days ago